A Long-term Follow-up Study of Patients With ARD103 CAR-T Cell Therapies

Trial statusNot yet recruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

AgeNot listed

SponsorARCE Therapeutics, Inc.

About this trial

This study will evaluate the long-term safety of ARD103 cellular therapies

The participant has R/R AML or MDS and has previously received ARD103 CAR-T cell therapies in the parent study.

The participant is able to understand and comply with protocol-required study procedures and has provided a written informed consent document.

There are no specific exclusion criteria for this study

49 Participants

are divided into 1 treatment group

Novant Health Cancer Institute28204, CharlotteNorth Carolina, United States

Novant Health Cancer Institute27201, Winston-SalemNorth Carolina, United States

MD Anderson Cancer Center77030, HoustonTexas, United States

ARCE Therapeutics, Inc.

Lead sponsor